Brief: Vaxart Receives Barda-Funded Award Valued Up To $453 Mln For A Phase 2B Study On Covid-19 Oral Pill Vaccine Candidate

Vaxart

13/06/2024 23:32

June 13 (Reuters) - Vaxart Inc  VXRT.O :
    * VAXART RECEIVES BARDA-FUNDED PROJECT NEXTGEN AWARD VALUED
UP TO
$453 MILLION TO CONDUCT A PHASE 2B STUDY EVALUATING ITS COVID-19
ORAL PILL VACCINE CANDIDATE
    * VAXART INC - VAXART ANTICIPATES INITIATING ENROLLMENT AS
EARLY
AS SUMMER 2024
    * VAXART - 10,000-SUBJECT PHASE 2B STUDY WILL EVALUATE
VAXART'S
NEXT GENERATION ORAL PILL COVID-19 VACCINE AGAINST AN APPROVED
MRNA VACCINE COMPARATOR
    * VAXART INC - INTERIM ANALYSIS FOR VACCINE EFFICACY
COMPARED TO
AN APPROVED MRNA COMPARATOR MAY OCCUR AS EARLY AS Q1 OF 2025

Source text for Eikon:  ID:nGNX7W0G5G 
Further company coverage:  VXRT.O 

 ((Reuters.Briefs@thomsonreuters.com;))